Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375g q4h and 4.5g q6h

Chemotherapy

Volumn 48, Issue 2, 2002, Pages 59-63

  Mattoes, Holly M ^a   Capitano, Blair ^a   Kim, Myo Kyoung ^a   Xuan, Dawei ^a   Quintiliani, Richard ^a   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL INFECTION; HUMAN; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL;

ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PENICILLANIC ACID; PIPERACILLIN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0036244510     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057663     Document Type: Article

References (19)

1. Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: Focus on ticarcillin/clavulanic acid
2. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models
3. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models
4. Continuous infusion beta-lactam: A pharmacodynamic approach
5. Antibiotic kinetics and dynamics for the clinician
6. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta lactam drugs
7. Comparative activity of cinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in the United States hospitals
8. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors
9. Multicenter study of in vitro susceptibility of the Bacteroides fragilisgroup, 1995 to 1996, with comparison of resistance trends from 1990 to 1996
10. In vitro activity of cefepime and other broad-spectrum beta lactams tested against 129 mec A-negative Staphylococcus spp. isolates: A multicenter sample
11. Epidemiology and in vitro susceptibility of drug-resistant Streptococcus pneumoniae
12. Susceptibility surveillance among gram-negative bacilli at a cancer center
13. Characteristics of pathogens causing urinary tract infections in hospitals in North America: Results from the SENTRY Antimicrobial Surveillance Program
14. Interactions of antimicrobial combinations in vitro: The relativity of synergism
15. Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosain cystic fibrosis
16. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cytic fibrosis
17. Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa
18. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens